SCHEDULE: Edesa Biotech: Nijhawan Group Ups Stake to 16.31%

An amendment to Schedule 13D reveals that Dr. Pardeep Nijhawan and associated entities now beneficially own approximately 16.31% of Edesa Biotech's common shares.

Summary

• This filing is an amendment (Amendment No. 11) to a Schedule 13D, updating beneficial ownership information for Edesa Biotech, Inc.
• Dr. Pardeep Nijhawan and associated entities (Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc., and The New Nijhawan Family Trust 2015) are the reporting persons.
• As of August 25, 2026, Dr. Pardeep Nijhawan may be deemed the beneficial owner of an aggregate of 2,613,492 Common Shares, representing approximately 16.31% of the Issuer's outstanding Common Shares.
• This ownership includes shares with sole and shared voting and dispositive power, encompassing directly held shares, shares underlying vested restricted stock units, options, warrants, Series A-1 Preferred Shares, and Series B-1 Preferred Shares.
• The filing notes that restricted stock units were granted to Dr. Pardeep Nijhawan in lieu of partial salary on July 2, 2026 (3,378 units) and August 3, 2026 (5,324 units), which vested in full upon grant.
• The total outstanding common shares considered for percentage calculation is 14,193,356 as of August 25, 2026, plus various other securities deemed outstanding for this reporting person.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the nature of a Schedule 13D amendment, which typically indicates changes in beneficial ownership or intentions, often associated with activist or strategic shifts rather than purely positive operational news.

Positives

• Dr. Pardeep Nijhawan's increased beneficial ownership to 16.31% may signal continued commitment and confidence in the company's long-term prospects.
• The granting of restricted stock units in lieu of salary suggests a focus on aligning management compensation with equity ownership.

Negatives

• Schedule 13D filings often indicate a shift in control or a potential activist stance, which can introduce uncertainty for other shareholders.
• The aggregation of ownership across multiple entities and security types can sometimes obscure the true nature of control and intent.

Risks

• Potential for future actions by the reporting persons that may not align with the interests of all shareholders.
• The complexity of the beneficial ownership calculation, including various convertible securities and options, could lead to misinterpretation of control.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance. It primarily focuses on updating beneficial ownership information.

Management Comments

• Restricted stock units were granted in lieu of partial salary.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common in the biotechnology sector, where significant ownership changes or strategic shifts by key individuals or investment groups can occur, often influencing stock performance.

Related Party Transactions

• Granting of restricted stock units to Dr. Pardeep Nijhawan in lieu of partial salary.

Stakeholder Impact

• Shareholders: Increased concentration of ownership by Dr. Nijhawan and associated entities may lead to shifts in corporate strategy or governance, impacting shareholder value.
• Employees: The use of restricted stock units for salary suggests a focus on equity-based compensation, potentially aligning employee and shareholder interests.

Next Steps

• Continued monitoring of Edesa Biotech, Inc. for any further filings or announcements related to changes in beneficial ownership or strategic direction by Dr. Pardeep Nijhawan and associated entities.

Key Dates

Recommendation

The filing indicates an increase in beneficial ownership by a key individual and associated entities, which could signal increased influence or strategic intent. However, without operational or financial updates, it's prudent to hold and observe future developments rather than making a definitive buy or sell decision.

Keywords

Schedule 13D, Beneficial Ownership, Edesa Biotech, Dr. Pardeep Nijhawan, Common Shares, Restricted Stock Units, Preferred Shares, Warrants